Loading
A phase 1/2 trial of IN10018 in melanoma, run by Hangzhou Hanx Biopharmaceuticals, Ltd., now recruiting.
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06708663 by Hangzhou Hanx Biopharmaceuticals, Ltd., with 124 participants planned, started 2025-01-17 and due to reach its primary completion in 2027-12-31. Interventions recorded: HX009+IN10018. Conditions listed: Biliary Tract Cancer, Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/